Early antibiotics delivered lifelong economic gains - but only where opportunity followed

Early antibiotics delivered lifelong economic gains - but only where opportunity followed

In the late 1930s and early 1940s pneumonia was the leading cause of infant mortality in the United States, accounting for one in ten deaths. It remains the leading cause of child death today, driven by deaths in developing countries.

The introduction of the first effective antibiotic treatments for pneumonia in 1937 did more than save the lives of children. New research shows that early access to the treatment had long term, lasting effects – translating into higher levels of education, greater employment rates, higher income and lower work-limiting disability in adulthood.

However, greater economic opportunities were not available for all who received the treatment. Researchers Sonia Bhalotra, Damian Clarke, and Atheendar Venkataramani show that although early access to antibiotics influenced economic outcomes decades later, those gains were not equally distributed.

By examining census microdata to track adults born just before and after the medical breakthrough, and adjusting for potential confounders, the research finds that Black Americans who faced higher pneumonia risk before antibiotics, saw larger health improvements and yet smaller returns in education and income. This was particularly significant in areas with entrenched racial discrimination which restricted their access to quality education and jobs. Women of both races also experienced smaller economic gains than men, reflecting the social and institutional barriers to women’s economic participation at the time.

Sonia Bhalotra, Professor of Economics at the University of Warwick said:

“Our findings highlight the role of opportunities in shaping the extent to which investments in early-life health translate into longer run economic gains.

“Despite a strong economic climate, systemic discrimination of Black Americans in the South that led to barriers to access to education and fair labour markets meant that potential economic gains from better early health were significantly constrained for this group.

“Medical innovation doesn’t automatically deliver economic benefits. they must be paired with efforts to dismantle structural barriers such as discrimination and gender inequality.”

Global health efforts tend to focus on measuring reduced mortality, but this study highlights the benefits to survivors. Accounting for these more widespread and persistent benefits magnifies returns to investing in childhood health. The findings therefore have strong implications for today’s global health policies.

Using robust historical data linking early health investment to future economic outcomes, the study demonstrates that even life-saving medical advances can fall short if communities lack fair access to opportunity.

• Read the full research paper: The Long Run Economic Effects of Medical Innovation and the Role of Opportunities